drugset / Trial / NCT06067828

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

NCT06067828

Phase 3 Completed 171 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory capacity (IC) and exercise endurance time.

Timeline

Start
2023-10-24
Primary completion
2026-01-22
Completion
2026-01-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 160 ug Inhaled
Comparator Formoterol Other / unclassified 4.8 ug Inhaled
Comparator Glycopyrronium Unknown 7.2 ug Inhaled